The Benefits of Intensive Glycemic Control in Elderly Patients With Type 2 Diabetes
NCT ID: NCT00850798
Last Updated: 2010-07-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
208 participants
INTERVENTIONAL
2009-02-28
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Populations worldwide are aging and type 2 diabetes is common in individuals aged \>80 years. The important issue that needs to be considered is whether tight glycemic control is benefits for elderly patients with type 2 diabetes. The benefits of intensive glucose control remain uncertain for the heterogeneous population of older diabetic patients due to a lack of clinical trial data evaluating the benefits of long-term intensive glucose control in older patients. This study is designed to provide reliable evidence on the balance of benefits and risks conferred by intensive glucose control in elderly patients with type 2 diabetes Methods: This is a prospective, randomized, open-labeled, controlled design to assess the benefits of treating elderly patients with type 2 diabetes. The study will include 208 elderly patients with type 2 diabetes and follow-up for 5 years. Eligible patients are randomized to receive intensive (A1C \<7.0%) or conservative (A1C around 8.0%) glycemic control. The primary study outcomes are a composite of macrovascular events and a composite of microvascular events, considered both jointly and separately. The secondary outcomes are death from any cause, death from cardiovascular causes, total coronary events, total cerebrovascular events, heart failure, peripheral vascular events, all cardiovascular events, and hospitalization for 24 hours or more.
Expected results: This study is designed to provide reliable evidence on the balance of benefits and risks conferred by intensive and conservative glucose control in elderly patients with type 2 diabetes. Once completed, this trial will clearly influence the management of elderly patients with type 2 diabetes, regardless of the results.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Incretin Based Therapy for Poorly Controlled Type 2 Diabetic Patients
NCT02026024
The Effects of add-on Anti-diabetic Drugs in Type 2 Diabetic Patients
NCT02885922
Effect of Internet Therapeutic Intervention on A1C Levels in Type 2 Diabetes Mellitus (DM)
NCT00814190
Effect of Low Glycaemic Index Diet on Blood Glucose Control in Chinese Type 2 Diabetic Patients
NCT01542554
Evaluation of Low Blood Sugar Events in Participants With Diabetes (MK-0431-401)
NCT01285076
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Fasting plasma glucose (mg/dL) 90 to 130 Glycated hemoglobin (%) 6.0 to 7.0
Intensive glycemic control
Intensive glycemic control
2
Fasting plasma glucose (mg/dL) 90 to 180 Glycated hemoglobin (%) 7.0 to 9.0
Conservative glycemic control
OADs and insulin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intensive glycemic control
Intensive glycemic control
Conservative glycemic control
OADs and insulin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Be able to walk by themselves
* They had their first diagnosis of type 2 diabetes mellitus at age 30 years or older.
Exclusion Criteria
* Overt clinical congestive heart failure (CHF) requiring treatment with a diuretic or ACE inhibitor.
* Previous documented cerebral or subarachnoid haemorrhage in the last 6 months
* Condition expected to severely limit survival
* Clinical diagnosis of dementia
* Resident in a nursing home
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Taipei Veterans General Hospital, Taiwan
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Institutional Review Board, Taipei Veterans General Hospital,Taiwan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chen-Hsen Lee
Taipei, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Harn-Shen Chen, MD, PhD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VGHIRB 97-12-04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.